An open label phase IIa trial evaluating the safety and efficacy of EPO906 in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer

Trial Profile

An open label phase IIa trial evaluating the safety and efficacy of EPO906 in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2011

At a glance

  • Drugs Patupilone (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top